AbbVie Halts Another Trial With I-Mab Antibody, Slashes Deal Size
Executive Summary
AbbVie is to terminate the clinical development of lemzoparlimab for myelodysplastic syndrome and acute myeloid leukemia and will also reduce the size of its 2020 deal with originator I-Mab by $445m, in the latest blow to the Chinese firm.
You may also be interested in...
Hidden Dragon? Investors Return To New China Biotech Reality
Several Chinese biotech developments during the Lunar New Year break have put investors on high alert, namely the continued share price slide of Chinese biotech bellwether WuXi Apptec, Lianbio ceasing operations and I-Mab divesting its China business to become a fully US-focused company.
AbbVie Exits CAR-T Cell Therapy Development Partnership With Caribou
Deal Snapshot: The companies had announced the deal back in February 2021, but citing its “strategic focus,” AbbVie told Caribou it was backing out.
Gilead’s Phase III Trial Halt Raises Questions About Magrolimab’s Value
While the myelodysplastic syndrome trial news seems unlikely to read through to other programs, MDS may have been the drug’s biggest market.